HANHUI Trademark

Trademark Overview


On Saturday, January 30, 2021, a trademark application was filed for HANHUI with the United States Patent and Trademark Office. The USPTO has given the HANHUI trademark a serial number of 79307453. The federal status of this trademark filing is REGISTERED as of Tuesday, June 28, 2022. This trademark is owned by Hanhui Pharmaceuticals Co., Ltd.. The HANHUI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for use in chemotherapy, radiotherapy, endocrine therapy, anesthesia; Pharmaceutical preparations for supplementing vitamins and nutrition, namely, dietary and nutritional supplements; Pharmaceutical preparations for anti-infection and antiviral purposes; Pharmaceutical preparations for improving lactation functions; Pharmaceutical preparations for treating hematological diseases, namely, anemia, leucocyte disorders, blood clots; Pharmaceutical preparations for treating cardiovascular and cerebrovascular diseases, namely, blood lipid disorder, blood pressure disorder, arrhythmia, cardiac insufficiency, angina pectoris, myocardial infarction; Pharmaceutical preparations for treating respiratory system diseases, namely, phlegm, cough, asthma; Pharmaceutical preparations for treating digestive system diseases and disorders, namely, peptic ulcer, diarrhea; Pharmaceutical preparations for treating central nervous diseases and disorders, namely, fever and pain, go...
hanhui

General Information


Serial Number79307453
Word MarkHANHUI
Filing DateSaturday, January 30, 2021
Status700 - REGISTERED
Status DateTuesday, June 28, 2022
Registration Number6770020
Registration DateTuesday, June 28, 2022
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 12, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations for use in chemotherapy, radiotherapy, endocrine therapy, anesthesia; Pharmaceutical preparations for supplementing vitamins and nutrition, namely, dietary and nutritional supplements; Pharmaceutical preparations for anti-infection and antiviral purposes; Pharmaceutical preparations for improving lactation functions; Pharmaceutical preparations for treating hematological diseases, namely, anemia, leucocyte disorders, blood clots; Pharmaceutical preparations for treating cardiovascular and cerebrovascular diseases, namely, blood lipid disorder, blood pressure disorder, arrhythmia, cardiac insufficiency, angina pectoris, myocardial infarction; Pharmaceutical preparations for treating respiratory system diseases, namely, phlegm, cough, asthma; Pharmaceutical preparations for treating digestive system diseases and disorders, namely, peptic ulcer, diarrhea; Pharmaceutical preparations for treating central nervous diseases and disorders, namely, fever and pain, gout, epilepsy, Parkinsonian syndrome, psychotic disorders, depression, anxiety, mania; Pharmaceutical preparations for treating geriatric diseases, namely, hyperosteogeny, prostatic hyperplasia, senile cataract; Pharmaceutical preparations for treating genitourinary system diseases, endocrine and metabolic system diseases and disorders, allergies, immune system diseases and disorders, liver and gall diseases, Alzheimer's diseases, skin diseases and disorders, obstetric and gynecological diseases and disorders, diseases with eye, ear, nose, mouth, oral cavity, and throat; Chemical preparations for pharmaceutical and medical purposes, namely, antineoplastic drugs, antibiotics, anti-infectives, vitamins and nutritional supplements, anesthetics, and those for treating hematological system diseases, cardiovascular and cerebrovascular diseases, endocrine and metabolic diseases and disorders, respiratory system diseases, digestive system diseases and disorders, central nervous system diseases and disorders, dermatological diseases, obstetric and gynecological diseases and disorders, ophthalmology and otorhinolaryngology diseases, and geriatric diseases; Analgesics; Medicines for humans, namely, antineoplastic drugs, anti-infectives, antibiotics, anesthetics, vitamin and nutritional supplements, and medicines for the treatment of allergy, cardiovascular and cerebrovascular diseases, dermatological diseases, geriatric diseases, and diseases with hematological system, genitourinary system, endocrine and metabolic system, immune system, respiratory system, digestive system, central nervous system, obstetrics and gynecology system, eye, ear, mouth, and throat; Sedatives; Tranquillizers; Biological preparations for medical purposes, namely, vaccines, antineoplastic preparations, antitoxin, and antisera; Antibiotics; Injectable pharmaceuticals, namely, antineoplastic drugs, anti-infectives, antibiotics, anesthetics, vitamin and nutritional supplements, and those for the treatment of allergy, cardiovascular and cerebrovascular diseases, dermatological diseases, geriatric diseases, ophthalmology and otorhinolaryngology diseases, and diseases with hematological system, genitourinary system, endocrine and metabolic system, immune system, respiratory system, digestive system, central nervous system, obstetrics and gynecology system; Tablets, namely, antineoplastic drugs, anti-infectives, antibiotics, anesthetics, vitamin and nutritional supplements, and tablets for the treatment of allergy, cardiovascular and cerebrovascular diseases, dermatological diseases, geriatric diseases, ophthalmology and otorhinolaryngology diseases, and diseases with hematological system, genitourinary system, endocrine and metabolic system, immune system, respiratory system, digestive system, central nervous system, obstetrics and gynecology system; Bulk medicines, namely, antineoplastic drugs, anti-infectives, antibiotics, anesthetics, vitamin and nutritional supplements, and medicines for the treatment of allergy, cardiovascular and cerebrovascular diseases, dermatological diseases, geriatric diseases, ophthalmology and otorhinolaryngology diseases, and diseases with hematological system, genitourinary system, endocrine and metabolic system, immune system, respiratory system, digestive system, central nervous system, obstetrics and gynecology system; Biochemical medicines, namely, antineoplastic drugs, anti-infectives, antibiotics, and medicines for the treatment of allergy, cardiovascular and cerebrovascular diseases, and diseases with hematological system, genitourinary system, endocrine and metabolic system, immune system, respiratory system, digestive system, and central nervous system; Blood for medical purposes; Herbal tinctures for medical purposes; Diagnostic preparations for medical purposes; Chemical reagents for medical or veterinary purposes; Radium for medical purposes; Radioactive substances for medical purposes; Isotopes for medical purposes; Radioactive medicines for medical imaging and the treatment of tumor and thyroid diseases; Oxygen for medical purposes; Chemical conductors for electrocardiograph electrodes; Semen for artificial insemination; Disinfectants for hygiene purposes; Disinfectants; Solutions for contact lenses; Contact lens cleaning preparations; Media for bacteriological cultures; Bouillons for bacteriological cultures; Bacteriological culture mediums; Nutritive substances for microorganisms for medical purposes; Cultures of microorganisms for medical and veterinary use; Disinfectant wipes; Wadding for medical purposes; Food for babies

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, March 26, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameHanhui Pharmaceuticals Co., Ltd.
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressCN

Party NameHanhui Pharmaceuticals Co., Ltd.
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressCN

Party NameHanhui Pharmaceuticals Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressCN

Trademark Events


Event DateEvent Description
Sunday, April 9, 2023NEW REPRESENTATIVE AT IB RECEIVED
Tuesday, November 1, 2022FINAL DECISION TRANSACTION PROCESSED BY IB
Thursday, October 6, 2022FINAL DISPOSITION NOTICE SENT TO IB
Thursday, October 6, 2022FINAL DISPOSITION PROCESSED
Wednesday, September 28, 2022FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sunday, August 21, 2022NEW REPRESENTATIVE AT IB RECEIVED
Tuesday, June 28, 2022NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, June 28, 2022REGISTERED-PRINCIPAL REGISTER
Tuesday, April 12, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 12, 2022PUBLISHED FOR OPPOSITION
Wednesday, March 23, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 8, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, March 8, 2022EXAMINER'S AMENDMENT ENTERED
Tuesday, March 8, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, March 8, 2022EXAMINERS AMENDMENT E-MAILED
Tuesday, March 8, 2022EXAMINERS AMENDMENT -WRITTEN
Thursday, February 3, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, February 2, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, February 2, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, January 28, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, January 28, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, January 28, 2022TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Friday, January 28, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, January 28, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, January 28, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, September 20, 2021REFUSAL PROCESSED BY IB
Saturday, August 28, 2021NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Saturday, August 28, 2021REFUSAL PROCESSED BY MPU
Tuesday, August 24, 2021NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, August 23, 2021NON-FINAL ACTION WRITTEN
Thursday, August 19, 2021ASSIGNED TO EXAMINER
Tuesday, March 30, 2021APPLICATION FILING RECEIPT MAILED
Friday, March 26, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 25, 2021SN ASSIGNED FOR SECT 66A APPL FROM IB